RxDoctor Payments Data

Callie Adams

Family · Baltimore, MDNPI 1952903411

Payments from drug & device makers

$554in general payments, 2019–2025

Across 31 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$183
  • Neos Therapeutics, LP$157
  • Neurocrine Biosciences, Inc.$72
  • AbbVie$30
  • Biohaven Pharmaceuticals, Inc.$24
  • Biohaven Pharmaceutical Holding Company Ltd.$23
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$554100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$554 in reported general payments places this provider in the 60th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$31,377
Medicare patients
182
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$26,965
Arnuity ElliptaFluticasone Furoate13$3,355
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,005
SynthroidLevothyroxine Sodium16$1,814
Levothyroxine Sodium60$970
Azelastine Hcl25$966
Atorvastatin Calcium92$944
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$889
Duloxetine Hcl20$568
Omeprazole21$462
Lisinopril74$420
ValacyclovirValacyclovir Hcl11$403
Fluticasone Propionate31$384
Losartan Potassium44$379
Montelukast Sodium15$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$30$1,81416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,843 family providers in Maryland.

Other family in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →